Accelerated concomitant boost radiotherapy and chemotherapy for advanced nasopharyngeal carcinoma

Journal of Clinical Oncology

Volumn 19, Issue 4, 2001, Pages 1105-1110

  Wolden, S L ^a   Zelefsky, M J ^a   Kraus, D H ^a   Rosenzweig, K E ^a   Chong, L M ^a   Shaha, A R ^a   Zhang, H ^a   Harrison, L B ^a   Shah, J P ^a   Pfister, D G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0035865281     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.4.1105     Document Type: Article

References (26)

1. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: Overall survival and patterns of failure
2. Immunogenetic aspects of nasopharyngeal carcinoma: IV. Increased risk in Chinese of nasopharyngeal carcinoma associated with a Chinese-related HLA profile (A2. Singapore 2)
3. Nasopharyngeal carcinoma: The Epstein-Barr virus association
4. An epidemiologic and clinical study of nasopharyngeal carcinoma
5. Interaction of factors associated with cancer of the nasopharynx
6. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099
7. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003
8. Concomitant chemotherapy-radiation therapy followed by hyperfractionated radiation therapy for advanced unresectable head and neck cancer
9. A prospective phase II trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in unresectable tumors of the head and neck
10. Nonparametric estimation from incomplete observations
11. Evaluation of survival data and two rank order statistics arising in its consideration
12. Carcinoma of the nasopharynx: Eighteen years' experience with megavoltage radiation therapy
13. Accelerated hyperfractionation radiation therapy for carcinoma of the nasopharynx: Techniques and results
14. Carcinoma of the nasopharynx: Factors affecting prognosis
15. Carcinoma of the nasopharynx treated by radiotherapy alone: Determinants of local and regional control
16. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: A positive effect on progression-free survival - International Nasopharynx Cancer Study Group: VUMCA I trial
17. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: Results of a 4-year multicenter randomized study
18. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma
19. Partially hyperfractionated accelerated radiotherapy and concurrent chemotherapy for advanced nasopharyngeal carcinoma
20. Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx
21. Management of unresectable malignant tumors at the skull base using concomitant chemotherapy and radiotherapy with accelerated fractionation
22. Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type
23. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer
24. Improved dose distributions for 3D conformal boost treatments in carcinoma of the nasopharynx
25. Intensity modulated radiotherapy for primary nasopharynx cancer